TY - JOUR
T1 - Mucosal delivery of adenovirus-based vaccine protects against ebola virus infection in mice
AU - Patel, Ami
AU - Zhang, Yi
AU - Croyle, Maria
AU - Tran, Kaylie
AU - Gray, Michael
AU - Strong, Jim
AU - Feldmann, Heinz
AU - Wilson, James M.
AU - Kobinger, Gary P.
N1 - Funding Information:
Potential conflicts of interest: none reported. Presented in part: Filoviruses: Recent Advances and Future Challenges, International Centre for Infectious Diseases Symposium, Winnipeg, Manitoba, Canada, 17–19 September 2006. Financial support: Public Health Agency of Canada; Canadian Institute for Health Research (grant MOP-43921 [to H.F.]). Supplement sponsorship is detailed in the Acknowledgments. Reprints or correspondence: Dr. Gary P. Kobinger, 1015 Arlington St., Winnipeg, Manitoba, R3E 3R2, Canada ([email protected]).
Funding Information:
Supplement sponsorship. This article was published as part of a supplement entitled “Filoviruses: Recent Advances and Future Challenges,” sponsored by the Public Health Agency of Canada, the National Institutes of Health, the Canadian Institutes of Health Research, Cangene, CUH2A, Smith Carter, Hemisphere Engineering, Crucell, and the International Centre for Infectious Diseases.
PY - 2007/11/15
Y1 - 2007/11/15
N2 - Background. Mucosal vaccination can offer several advantages over conventional intramuscular immunization to protect against Ebola virus (EBOV) infection, such as immune protection at sites of viral entry into susceptible individuals, and can be administered using needle-free devices. Methods. The present study evaluated oral and nasal vaccination of mice with human adenovirus serotype 5 (Ad) expressing the Zaire ebolavirus glycoprotein (Ad-ZGP) in terms of their protection against and underlying immune responses to EBOV. Results. Similar to intramuscular administration, oral or nasal vaccination of mice with Ad-ZGP fully protected the mice against a lethal challenge with mouse-adapted EBOV. Both T and B cell responses developed in mice receiving oral or nasal vaccination in different body compartments, indicating qualitative improvement of the immune response after mucosal immunization, compared with intramuscular vaccination. Conclusions. Overall, the breadth of the immune response noted after nasal or oral immunization, including stimulation of CD8+ T cells or effector memory T cells from the gastrointestinal tract or the lungs, was superior to that noted after intramuscular administration of the vaccine. The present study showed that adenovirus-based vaccine is effective against EBOV infection in mice after oral and nasal immunization.
AB - Background. Mucosal vaccination can offer several advantages over conventional intramuscular immunization to protect against Ebola virus (EBOV) infection, such as immune protection at sites of viral entry into susceptible individuals, and can be administered using needle-free devices. Methods. The present study evaluated oral and nasal vaccination of mice with human adenovirus serotype 5 (Ad) expressing the Zaire ebolavirus glycoprotein (Ad-ZGP) in terms of their protection against and underlying immune responses to EBOV. Results. Similar to intramuscular administration, oral or nasal vaccination of mice with Ad-ZGP fully protected the mice against a lethal challenge with mouse-adapted EBOV. Both T and B cell responses developed in mice receiving oral or nasal vaccination in different body compartments, indicating qualitative improvement of the immune response after mucosal immunization, compared with intramuscular vaccination. Conclusions. Overall, the breadth of the immune response noted after nasal or oral immunization, including stimulation of CD8+ T cells or effector memory T cells from the gastrointestinal tract or the lungs, was superior to that noted after intramuscular administration of the vaccine. The present study showed that adenovirus-based vaccine is effective against EBOV infection in mice after oral and nasal immunization.
UR - http://www.scopus.com/inward/record.url?scp=38449120080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38449120080&partnerID=8YFLogxK
U2 - 10.1086/520603
DO - 10.1086/520603
M3 - Article
C2 - 17940978
AN - SCOPUS:38449120080
SN - 0022-1899
VL - 196
SP - S413-S420
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - SUPPL. 2
ER -